Living Cell Technologies Ltd (LCT), based in New Zealand, has initial data regarding their transplanted pig islet-cell system that had been implanted in 8 subjects in Russia in 2007. Safety review results will be presented at this year's Annual Meeting of the American Diabetes Association in two months.
"We are pleased that our treatment has shown so far to be safe and well tolerated," LCT founder and medical director Professor Bob Elliot said on Wednesday.
"We are encouraged that we have demonstrated (the transplant treatment) may be safely administered up to three times and that we have seen evidence of continuing efficacy."
None of the patients showed signs of any pig-related disease.
Six subjects showed some degree of improvement in blood sugar control. Two subjects were able to discontinue insulin for at least one month, one for 8 months.
Trials are now being designed that will study the impact of transplanting larger doses of the insulin-producing pig cells.
If things go well, this is at least a "temporary cure" for Type 1 diabetes. It had been more than two years since hearing of the initial success of the trial. The full current article is here.
Six subjects showed some degree of improvement in blood sugar control. Two subjects were able to discontinue insulin for at least one month, one for 8 months.
Trials are now being designed that will study the impact of transplanting larger doses of the insulin-producing pig cells.
If things go well, this is at least a "temporary cure" for Type 1 diabetes.
It had been more than two years since hearing of the initial success of the trial .
The full current article is here .